In a global first, gene therapy that could prove life-saving for children has been recommended for approval in Europe.
The pioneering technology to fix faulty genes has been developed by Italian scientists and GlaxoSmithKline
FOX News reports:
The European Medicines Agency (EMA) said on Friday it had endorsed the therapy, called Strimvelis, for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID) for whom no matching bone marrow donor is available.
Around 15 children a year are born in Europe with the ultra-rare genetic disorder, which leaves them unable to make a type of white blood cell. They rarely survive beyond two years unless their immune function is restored with a suitable bone marrow transplant.
Read More:DNA: How Technology Plays A Major Role In The Beast System
Read More:New Scientific Theory Suggests That Those With Blood Type RH Negative Could Belong To A Non-Human Lineage
Read More:Corrupting The Image Of God: GMO Scientists Now Developing Techniques To Intentionally Pollute Natural Organism’s Genomes To Permanently Alter Their DNA